---
title: "Eli Lilly's Market Cap Balloons Again On This IPO's Setback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291971712.md"
description: "On Tuesday, shares of Eli Lilly surged to an all-time high following disappointing test outcomes from newly listed IPO company, Kailera Therapeutics, regarding their weight-loss medication. This setback caused a significant increase in Eli Lilly's market capitalization."
datetime: "2026-07-07T19:45:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291971712.md)
  - [en](https://longbridge.com/en/news/291971712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291971712.md)
generator: "portal-rs"
---

# Eli Lilly's Market Cap Balloons Again On This IPO's Setback

On Tuesday, shares of Eli Lilly surged to an all-time high following disappointing test outcomes from newly listed IPO company, Kailera Therapeutics, regarding their weight-loss medication. This setback caused a significant increase in Eli Lilly's market capitalization.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)

## Related News & Research

- [Is Eli Lilly Stock Outperforming the Dow?](https://longbridge.com/en/news/297309786.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)
- [Lilly's Cost-Saving Study Leaves Out Zepbound's Price](https://longbridge.com/en/news/297077502.md)
- [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md)
- [Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label](https://longbridge.com/en/news/297356212.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**